About Jubilant Therapeutics

Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB.

Press Release

Jubilant Life Sciences Announces Appointment of Dr. Syed Kazmi as President and CEO of its New Innovative Biopharmaceutical Company in the U.S. – Jubilant Therapeutics Inc.

Yardley, PA, United States; Sep 09, 2019

Jubilant Life Sciences Limited has announced that Dr. Syed Kazmi, PhD, MBA, will join its new innovative biopharmaceutical company in the U.S., Jubilant Therapeutics Inc., as President and Chief Executive Officer.

Dr. Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for Oncology.

Business Model and Strategy

  • Discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically defined patient populations
  • Focus on unmet medical needs resulting from drug resistance or specific genetic modifications or compensatory mechanism
  • Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries
  • Fast track promising assets from discovery to clinical
  • Leverage synergistic capabilities of Jubilant Life Sciences www.jubl.com value chain and dedicated world-class biology and chemistry research services division

Key Differentiators

  • Agile business model geared for speed, efficiency and creative partnerships to rapidly bring new cures to market
  • Dedicated highly skilled scientists under the leadership of experienced drug hunters, with a proven, world-class discovery engine
  • Highly efficient platform that uniquely integrates patient-derived database, structure-based design and computational architecture to discover and develop novel, precision therapeutics
  • Fast track promising assets from discovery to clinical
  • First-in-class programs and strong IP portfolio:
    • The only known dual epigenetic inhibitor of LSD1/HDAC6 is positioned to leverage specific tumor types that are dependent on both these targets
    • First-in-class PAD4 inhibitor with potential to address unmet needs in multiple auto-immune disorders


*additional early stage programs in stealth mode

Partnering and Collaborations

Jubilant Therapeutics is open for partnering or collaborations with:

  • Pharma and Biotech companies at appropriate stage to accelerate clinical development andmarket approval of our ongoing programs, discover/develop new programs in synergistic areas or conduct research with our drug candidates either as monotherapy/ in combination to improve existing therapies in cancer
  • Academia and Biotech/Pharma for in-licensing and supporting our pre-clinical activities
  • If you are interested in collaborating with us, please contact: BD@jubilantTx.com


Drop a line to Rajiv.Tyagi@jubilantTx.com to schedule a meeting at the event


U.S Office
Jubilant Therapeutics Inc

1430 Route 206, Suite 110
Bedminster, NJ 07921,
United States

Phone: +1 267-888-4319